Further in vivo studies should clarify whether inhibition of NF-κB signaling or TNF-α production results in protective effects, and if the NF-κB pathway results a convenient new target for the development of therapeutic strategies for the treatment of CNS commitment in HUS patients. The gene discussed is TNF; the disease is hemolytic-uremic syndrome.